Royalty Report: Drugs, Cancer, Disease – Collection: 256489


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • DNA
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 256489

License Grant
The Company has agreed to pay Licensor a royalty of the net sales derived from two specified CAR-T products.
License Property
CAR-T products are therapies, which are genetically engineered synthetic receptors that recognize a specific antigen expressed on tumor cells.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 74574

License Grant
This letter of intent with a Chinese Licensor is for Super Antigen Receptor T cell (CAR-T) cocktail therapy, patents pending, manufacturing technology, and clinical data of the aforementioned therapies.
License Property
CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack cancer tumors.
Field of Use
The Super CAR –T Cocktail therapy has shown promise in early human clinical trials for the treatment of blood cancer, renal, cervical and hepatic cancer.

IPSCIO Record ID: 336357

License Grant
For the Exclusive License, the French Licensor grants an exclusive, even as to, except Licensor to the extent necessary for Licensor to perform its obligations under the Research Program, license under the Licensor Intellectual Property (excluding TAL Patent Rights), to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Licensee Licensed Products in the Field in the Territory, with the right to sublicense.

For the TAL Patent Rights, Licensor grants the right to use the TAL nucleases engineered by Licensor pursuant to this Agreement to Develop Licensee license products until the filing of an IND for each Licensee Licensed Product, in the Field.

Also, for an Exclusive License, Licensor grants an exclusive ( even as to Licensor) license under the TAL Patent Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize such Licensee Licensed Product in the Field in the Territory.

For the Right of Reference, Licensor grants a Right of Reference, to any data Controlled by Licensor that relates to the Licensed Licensor Intellectual Property, the Agreement CAR-Ts, the Licensee Licensed Products or preclinical studies with respect to the Licensee Licensed Products and that Licensee reasonably believes may be necessary or useful to the Development.

For the License to Licensor Improvements, Licensor grants a nonexclusive, worldwide, sublicensable, perpetual and irrevocable license under any Licensor Improvements that were solely or jointly invented by the employees, agents or independent contractors of Licensee to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and processes.

License Property
Licensor has developed and controls proprietary rights to certain technology relating to adoptive immunotherapy CART-cell and genome engineering technologies.

Agreement CAR-T means any CAR-T utilizing the Licensor Technology that is identified, created or developed Targeting a Licensee Target.

CAR means a chimeric antigen receptor expressed from an experimentally validated Licensor viral construct with specific molecular architecture and signaling domain sequences.

CAR-T means a population of T-cells with a unique set of experimentally validated biologic attributes expressing a CAR construct produced using Licensor Technology.

Patents include
TAL Effector-mediated DNA modification,
Modular DNA binding domains and methods of use, and
Method for treating materials with pulsed electric field, and other patents.

CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient’s own T-cells to target tumor cells).

Field of Use
The global strategic collaboration is to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.

The Field means human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes.

The Parties are collaborating to discover and research novel CAR-Ts active against certain designated targets and to provide for Licensee to further research, develop, manufacture and commercialize such CAR-Ts and products containing such CAR-Ts.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.